Novo Nordisk considers higher bid for Ablynx (Google Translate)
Danish pharma giant Novo Nordisk [CPH: NOVO-B] is considering a higher bid for Belgian biotech company Ablynx [EBR: ABLX], according to a newswire report. The Bloomberg report cited unnamed sources.
According to Belgian daily De Tijd, another unnamed source has denied this piece of information. The new bid is expected early next week.
Novo Nordisk's first bid was at EUR 30.5 per share, for EUR 2.6bn in total. Ablynx rejected the bid because it was aiming for over EUR 40 per share. CEO Edwin Moses claimed the Danish were undervaluing the people and the technology of the Ghent-based company.
It is unclear how much higher the new bid will be, the report added.
Link to original source (De Tijd)